- Home
- QNRX vs NDRA Comparison
QNRX vs NDRA Comparison
Compare QNRX & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- NDRA
- Stock Information
- Founded
- QNRX 2018
- NDRA 2007
- Country
- QNRX United States
- NDRA United States
- Employees
- QNRX N/A
- NDRA N/A
- Industry
- QNRX Medical/Dental Instruments
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- QNRX Health Care
- NDRA Health Care
- Exchange
- QNRX Nasdaq
- NDRA Nasdaq
- Market Cap
- QNRX 2.5M
- NDRA 2.1M
- IPO Year
- QNRX N/A
- NDRA 2017
- Fundamental
- Price
- QNRX $7.12
- NDRA $3.98
- Analyst Decision
- QNRX
- NDRA Strong Buy
- Analyst Count
- QNRX 0
- NDRA 1
- Target Price
- QNRX N/A
- NDRA $50.00
- AVG Volume (30 Days)
- QNRX 355.0K
- NDRA 355.0K
- Earning Date
- QNRX 05-08-2025
- NDRA 05-13-2025
- Dividend Yield
- QNRX N/A
- NDRA N/A
- EPS Growth
- QNRX N/A
- NDRA N/A
- EPS
- QNRX N/A
- NDRA N/A
- Revenue
- QNRX N/A
- NDRA N/A
- Revenue This Year
- QNRX N/A
- NDRA N/A
- Revenue Next Year
- QNRX N/A
- NDRA N/A
- P/E Ratio
- QNRX N/A
- NDRA N/A
- Revenue Growth
- QNRX N/A
- NDRA N/A
- 52 Week Low
- QNRX $5.01
- NDRA $2.97
- 52 Week High
- QNRX $54.95
- NDRA $665.00
- Technical
- Relative Strength Index (RSI)
- QNRX 46.54
- NDRA 51.65
- Support Level
- QNRX $5.27
- NDRA $3.28
- Resistance Level
- QNRX $7.22
- NDRA $3.98
- Average True Range (ATR)
- QNRX 1.12
- NDRA 0.92
- MACD
- QNRX 0.22
- NDRA 0.02
- Stochastic Oscillator
- QNRX 62.79
- NDRA 31.76
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.